(Q35101116)

6 August 2017

1 reference

title

Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism (English)

1 reference

6 August 2017

1 reference

Daniel J Rader

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

7A

1 reference

6 August 2017

page(s)

18E-23E

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Fluvastatin with and without niacin for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

High Density Lipoprotein Metabolism in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Role of fibrates in the management of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

n-3 fatty acids and lipoproteins: comparison of results from human and animal studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903384-2

10.1016/S0002-9149(02)03384-2

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference